"Going on record very conservatively, after spending some time speaking to insiders and studying the company closely, we see this as an $8 to $10 stock in twelve to fifteen months," writes M.E. Garza of BioMedReports. "We continue to look for a very positive news flow from Cytrx and some key developments ahead."
The complete report is available now at BioMedReports.Com:
Market Data 
Markets 
AI
